Blepharospasm
Conditions
Brief summary
The purpose of this study is to compare the effectiveness of 3 doses of Dysport® with placebo by assessing functional disability in blepharospasm.
Interventions
BIOLOGICALBotulinum toxin type A
Sponsors
Ipsen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients with a confirmed diagnosis of bilateral benign essential blepharospasm, and having symptoms of such for at least 6 months prior to the baseline visit * naïve patients to botulinum toxin type A treatment, or patients who had received a single treatment of botulinum toxin type A, or those who had demonstrated a satisfactory response, in the investigator's opinion, to the last 2 injections of botulinum toxin type A with a minimum of 12 weeks since the last injection and where a further injection at full dosage was now indicated * patients with a minimum score of 8 on the BDS
Exclusion criteria
* patients with either neuroleptic-induced blepharospasm, isolated levator dysfunction or apraxia * previous surgical, chemical and thermal myectomy or neurectomy * any condition where intramuscular injection is contraindicated * ophthalmolgical infection * myasthenia gravis or other disorders of the neuromuscular junction * prescription of antispastic, muscle relaxants or medications affecting neuromuscular junction transmission, or medication where the dose or choice of medication has not been constant for the last 30 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The functional disability as measured by the percentage of normal activity (PNA) derived from the Blepharospasm Disability Scale (BDS) at 4 weeks post-treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| PNA, FIM and SRS at 8, 12 and 16 weeks post-treatment. | — |
| Severity of global impairment due to blepharospasm as measured by the Visual Analogue Scale (VAS) at 4, 8, 12 and 16 weeks post-treatment. | — |
| Change from baseline in BDS, FIM, severity of oculo-facial spasm and in severity of global impairment due to blepharospasm (measured by VAS) at 4, 8, 12 and 16 weeks post treatment. | — |
| Frequency of involuntary movements (FIM) and severity of oculo-facial spasm (measured by the Severity Rating Scale [SRS]) at 4 weeks post-treatment. | — |
| Patient assessment of benefit and need for re-treatment, evaluated at the end of the study. | — |
| Investigator assessment of benefit and need for re-treatment, evaluated at the end of the study. | — |
| To compare the safety of each of the 3 doses of Dysport with placebo in terms of adverse event incidence, vital signs and physical examinations. | — |
| Percentage of patients withdrawn from the study due to lack of efficacy at each assessment point. | — |
Countries
United States
Outcome results
None listed